Key result
In vitro eicosatetraynoic acid prevents irreversible second-phase platelet aggregation in diabetics by inhibiting prostaglandin synthesis.
Why the study?
Does 5, 8, 11, 14-eicosatetraynoic acid (TYA) prevent irreversible second-phase aggregation of platelets from diabetic patients in vitro?
Population
Platelets from diabetic patients (in vitro model)
Design
Preclinical
Authors
Loading...
Indicates diabetic platelets share prostaglandin-dependent mechanisms with normal platelets; supports mechanistic research but should not yet change practice.
Does 5, 8, 11, 14-eicosatetraynoic acid (TYA) prevent irreversible second-phase aggregation of platelets from diabetic patients in vitro?
Inhibition of prostaglandin synthesis by TYA prevents irreversible second-phase platelet aggregation in diabetic patients in vitro, indicating their platelets are controlled by similar intracellular mechanisms as normal individuals.
John A. Colwell (1975) studied Diabetes Mellitus. 5, 8, 11, 14-eicosatetraynoic acid (TYA) was evaluated on Irreversible second-phase aggregation of platelets. In vitro application of 5, 8, 11, 14-eicosatetraynoic acid (TYA) prevented irreversible second-phase aggregation of platelets in diabetic patients by inhibiting prostaglandin synthesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: